| A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. | |
| | |
MedLine Citation:
|
PMID: 17121873 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To assess the tolerability and effectiveness of 105AD7 vaccination in colorectal cancer patients. 105AD7 is a human anti-idiotypic antibody mimicking CD55, a glycoprotein, which is more than expressed on colorectal cancer cells and protects them from attack by complement. EXPERIMENTAL DESIGN: Colorectal cancer patients (n = 67) eligible for primary surgery were randomized to receive the anti-idiotypic antibody 105AD7+/-Bacillus Calmette-Guerin/alum or to no treatment (control group). The immunizations were given i.d./i.m. before surgery and continued for a period of 2 years. The patients were monitored in enzyme-linked immunospot (ELISPOT; gamma-IFN), proliferation assay, and Luminex cytokine assays. RESULTS: No serious adverse events were recorded. Of the 32 investigated immunized patients, 14 (44%) were considered to be responders in the ELISPOT assay. Induced proliferative responses were noted in 17 of 40 (43%) monitored patients. There was no correlation between the ELISPOT and proliferation assays. Luminex analyses revealed tumor necrosis factor-alpha and granulocyte macrophage colony-stimulating factor responses not only to the vaccine but also toward the native antigen CD55 in 9 of 13 (69%) patients. CONCLUSIONS: Immune responses to vaccination were induced in a majority of monitored patients measured by ELISPOT and proliferation assay. The lack of correlation between the ELISPOT and proliferation assays may reflect the fact that the two methods measure different T-cell responses and highlights the importance of multiple readouts in evaluating a potential cancer vaccine. Responses to both the anti-idiotype and the CD55 antigen were measurable, adding support to the use of CD55 as a target in cancer treatment. |
| | |
Authors:
|
Gustav J Ullenhag; Ian Spendlove; Nicholas F S Watson; Adrian A Indar; Mukul Dube; Richard A Robins; Charles Maxwell-Armstrong; John H Scholefield; Lindy G Durrant |
Related Documents
:
|
23044983 - Traditional medicines, collective negotiation, and representations of risk in indian ca... 22344713 - Increased expression of mir-148b in ovarian carcinoma and its clinical significance. 14602243 - Cancer care in chile. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2006-11-22 |
Journal Detail:
|
Title: Clinical cancer research : an official journal of the American Association for Cancer Research Volume: 12 ISSN: 1078-0432 ISO Abbreviation: Clin. Cancer Res. Publication Date: 2006 Dec |
Date Detail:
|
Created Date: 2006-12-25 Completed Date: 2007-03-15 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 9502500 Medline TA: Clin Cancer Res Country: United States |
Other Details:
|
Languages: eng Pagination: 7389-96 Citation Subset: IM |
Affiliation:
|
Academic Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
therapeutic use Adult Aged Aged, 80 and over Antibodies, Anti-Idiotypic / therapeutic use* Antigens, CD55 / immunology Cancer Vaccines / therapeutic use* Carcinoma / immunology, therapy* Cell Proliferation Colorectal Neoplasms / immunology, therapy* Cytokines / blood Female Humans Immunization, Passive / methods Interferon-gamma / blood Lymphocyte Activation / immunology Male Middle Aged Molecular Mimicry / immunology Neoadjuvant Therapy T-Lymphocytes / immunology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/105AD7 antibody; 0/Adjuvants, Immunologic; 0/Antibodies, Anti-Idiotypic; 0/Antigens, CD55; 0/Cancer Vaccines; 0/Cytokines; 82115-62-6/Interferon-gamma |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital ma...
Next Document: RNASEN regulates cell proliferation and affects survival in esophageal cancer patients.